NASDAQ:MBRX Moleculin Biotech Q2 2024 Earnings Report $0.51 +0.01 (+1.16%) As of 01:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Moleculin Biotech EPS ResultsActual EPS-$2.23Consensus EPS -$2.10Beat/MissMissed by -$0.13One Year Ago EPSN/AMoleculin Biotech Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMoleculin Biotech Announcement DetailsQuarterQ2 2024Date8/13/2024TimeN/AConference Call DateWednesday, August 14, 2024Conference Call Time8:00AM ETUpcoming EarningsMoleculin Biotech's Q3 2025 earnings is scheduled for Friday, November 14, 2025, with a conference call scheduled on Wednesday, November 12, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Moleculin Biotech Earnings HeadlinesMoleculin Biotech (NASDAQ:MBRX) Lowered to "Strong Sell" Rating by Wall Street ZenOctober 5, 2025 | americanbankingnews.comMoleculin Biotech announces issuance of Canadian patent covering AnnamycinSeptember 26, 2025 | finance.yahoo.comYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.October 9 at 2:00 AM | Priority Gold (Ad)Moleculin Biotech Secures Canadian Patent for AnnamycinSeptember 25, 2025 | msn.comMoleculin Announces Notice of Allowance for Canadian Patent Covering AnnamycinSeptember 25, 2025 | globenewswire.comMoleculin Biotech files to sell 64.86M shares of common stock for holdersSeptember 19, 2025 | msn.comSee More Moleculin Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Moleculin Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Moleculin Biotech and other key companies, straight to your email. Email Address About Moleculin BiotechMoleculin Biotech (NASDAQ:MBRX) is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need. The company’s pipeline includes multiple product candidates at various stages of development. WP1066 is an immunotherapeutic compound designed to inhibit the STAT3 signaling pathway, which is implicated in the growth and survival of certain brain tumors and other malignancies. Annamycin is an anthracycline derivative engineered to overcome resistance mechanisms in acute myeloid leukemia (AML) with the goal of improving safety and efficacy. In addition, Moleculin is advancing WP1220, a broad-spectrum antiviral candidate targeting poxviruses and coronaviruses through inhibition of viral replication. Headquartered in Houston, Texas, Moleculin Biotech collaborates with academic institutions and contract research organizations to conduct its preclinical and clinical studies. The company’s development programs include Phase 1 and Phase 2 clinical trials in the United States, with plans to initiate additional studies in international markets as regulatory approvals are secured. Such partnerships and trial sites enable Moleculin to advance its candidates efficiently through the clinical development pathway. Founded in 2012, Moleculin Biotech is led by Walter Klemp, President and Chief Executive Officer, a veteran in the biotech industry with experience in drug development and corporate strategy. Under his leadership, the company continues to expand its research capabilities and global trial network, aiming to bring its innovative therapies to patients with critical oncological and viral diseases.View Moleculin Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings Fastenal (10/13/2025)BlackRock (10/14/2025)Citigroup (10/14/2025)The Goldman Sachs Group (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)Wells Fargo & Company (10/14/2025)ASML (10/15/2025)Abbott Laboratories (10/15/2025)Bank of America (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
